Currently, only 10% of the drugs that enter Phase I receive marketing approval from the U.S. Food and Drug Administration (FDA), with unmanageable toxicity accounting for approximately 30% of the ...
T Cell Engagers (TCEs) are bispecific antibodies that target both tumor-associated cell surface antigens (TAA) and T-cell surface receptors (TCR). TCE bispecific antibodies have a major advantage over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback